PubMed Health⌕ Search

Biomedical subjects

J J van Rood

Publications and source records attributed to J J van Rood.

At least 37 records · Page 2Linked to original sources
PubMed1978

Matching for HLA antigens of A, B, and DR loci in renal transplantation by Eurotransplant.

79 patients and their respective cadaveric kidney donors were typed for HLA-A, HLA-B, and HLA-DR antigens using frozen stored spleen lymphocytes and fresh peripheral-blood lymphocytes. The kidney-graft survival-rate at 3 to 18 months was highest when donor and recipient shared one or two DR antigens and three or four A and B antigens. The graft-survival rate was significantly higher (87 +/- 6%) at 18 months in these patients than in less well matched patients (48 +/- 9%).

Epitopes↗
PubMed1978

Influence of a single blood transfusion on kidney allograft survival in unrelated rhesus monkeys.

A prospective study was performed in moderately immunosuppressed unrelated rhesus monkeys to investigate the influence of a single transfusion on kidney allograft survival. The recipients received either whole citrated blood or plasma-free transfusates consisting of pure red blood cell or lymphocyte suspensions. Except for one group, in which blood and kidney donors were optimally matched, transfusions and kidney allografts were disparate for two to four A/B locus antigens with the recipients. Transfusions were given 2 to 4 weeks before kidney grafting, except in one experimental group where the recipients were transfused 0 to 12 hr before transplantation. The general trend was that graft prolongation could be obtained with all experimental protocols. However, it was also shown that a single transfusion entails the risk of accelerated rejection. This adverse effect was not observed in the animals receiving blood and kidneys from donors optimally matched for A/B locus antigens and in recipients transfused shortly before or during transplantation. These results may contribute to a further improvement of the current clinical transfusion policy.

Animals↗
PubMed1978

Can anti HLA-A and -B antibodies inhibit the MLC test?

Eleven lymphocytotoxic pregnancy sera were tested for inhibition in the MLC test. Responder inhibition and stimulator inhibition were analyzed separately by using cells from the serum producer as stimulator and responder respectively. Only three sera showed inhibitionof responder function, whereas all sera showed inhibition of stimulator function. The specificity of the latter inhibition was at least in part attributable to antibodies directed to specificities other than B-cell specificities (presumed to be coded for in the HLA-D region). This was deduced from the fact that platelet eluates devoid of anti B-cell antibodies effectively inhibited in MLC.

Antibody Specificity↗
PubMed1978

Genetic basis of gluten-sentitive enteropathy.

Families of patients with gluten-sensitive enteropathy (GSE) were typed for HLA-A and -B antigens as well as for HLA-DW3 antigen(s) using appropriate typing alloantisera. In addition, patients and families were typed for GSE-associated B cell antigens using alloantisera obtained from mothers and wives of patients. The data obtained suggest that disease occurs within families when two conditions were fulfilled: (1) the family member is homozygous for the GSE-associated B cell antigens and (2) the family member also bears the HLA-DW3 antigen(s) or an antigen usually associated with DW3. In addition, with the family studies it was possible to show that the gene(s) controlling the DW3 antigen(s) and those controlling the GSE-associated B cell antigens are separate nonlinked genetic loci, a fact which leads to the conclusion that GSE has a genetic basis in at least two genes. It is speculated that the genes responsible for GSE code for surface proteins which are physically associated on lymphoid cell membranes and which form receptors important to the initiation of disease.

B-Lymphocytes↗
PubMed1978

Treatment of aplastic anaemia by antilymphocyte globulin with or without marrow infusion.

Forty-one patients, suffering from severe aplastic anaemia were treated either with ALG alone (27 patients) or ALG followed by infusion of allogeneic bone marrow (14 patients). Eighteen patients (67 per cent) are presently alive after ALG alone at over 100 to over 550 days. Fourteen (52 per cent) showed sustained improvement of haematopoiesis, two are alive without change, one recovered autologous haematopoiesis after cyclophosphamide conditioning and transfusion of HLA identical marrow and one is lost to follow-up. Eight patients (57 per cent) are currently alive after ALG and transfusion of haplotype identical marrow with self-sustaining autologous haematopoiesis at over 200 days to over four and a half years. No lethal complications occurred and none of the bone marrow infusions led to permanent engraftment or graft-versus-host disease. The mechanism of action is not known, but our results support the hypothesis that unspecified autoimmune reactions block the normal outgrowth of haematopoietic precursor cells in a substantial number of patients with aplastic anaemia. This therapeutic approach seems to offer good chances of survival, especially for those patients who do not have an HLA identical sibling. Its value should be further investigated.

Anemia, Aplastic↗
PubMed1978

Platelet transfusion therapy. Optimal donor selection with a combination of lymphocytotoxicity and platelet fluorescence tests.

Although the value of HLA matching for the selection of platelet donors for patients refractory to random platelets is beyond doubt, even perfectly matched combinations sometimes fail to give a satisfactory transfusion response. With HLA typing and negative lymphocytotoxicity crossmatches, 35% of the platelet transfusions administered to 15 patients gave disappointing results (29 of 82). Additional crossmatching with the newly developed platelet fluorescence test described in this paper reduced the unexpected transfusion failures to 7% (6 of 82). Five of these failures were observed in one patient. The target of the antibodies detected with this platelet fluorescence test is not yet fully specified. It seems probable that both HLA and platelet-specific non-HLA antibodies were detected. No correlation of the results of platelet transfusions with the presence or absence of leukoagglutinating antibodies was found.

Blood Donors↗
PubMed1977

[Immunologic HLA-typing. A tool for selection of recipients in transplantation and for detection of disposition to certain diseases (author's transl)].

Some decades ago, animal experiments have shown that inbred mice with completely identical genetic characteristics accept transplants between each other without any problem while transplants between individuals of genetically different strains are being rejected after a few days. It was also proven later that with men, genetical factors are responsible for acceptance or rejection of homologous transplants. These genetic factors, although they are called the HLA system, are located on the sixth chromosome. Methods were developed to determine the inherited HLA antigens with the help of antibodies present in the blood serum of pregnant women. The determination is of great importance in preparing transplants organ, especially of kidneys, because chances of successful transplantation are the greater, the better the correspondence of HLA antigens between donor and recipient. Furthermore, there exists growing indication that HLA antigens are coupled or even partly identical with the immune response gene products. These determine whether an individual is more or less suited to develop an immunity against bacterial or viral infections. Finally, there subsist associations of certain HLA antigens and diseases such as gluten enteropathy, myasthenia gravis, multiple sclerosis, diabetes mellitus and many others.

Animals↗
PubMed1977

Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions.

29 patients with severe aplastic anaemia were treated with either antilymphocyte globulin (A.L.G.) alone (15 patients) or A.L.G. followed by infusion of allogeneic bone-marrow (14 patients). The overall response to both forms of treatment in terms of 1-year survival was 55%; 12 of the 29 patients showed a sustained haematological improvement, during a period of observation of up to 4 1/2 years. No potentially fatal complications were observed. None of the bone-marrow infusions led to a permanent "take" or graft-versus-host disease. How A.L.G. acts is unknown, but our findings accord with the hypothesis that, in a substantial proportion of cases of aplastic anaemia, unspecified autoimmune reactions block the development of residual stem cells A.L.G. seems to offer a good chance of survival, especially for those patients who do not have HLA-matched siblings. Its value should be further established.

Adolescent↗
PubMed1977

In vitro immune responsiveness to vaccinia virus and HLA.

Because several lines of evidence suggest that HLA products might have an important function in the immune response to infectious agents, we studied the possible relation between immune response to vaccinia virus and HLA phenotype in 79 soldiers who received a primary vaccination. A low in vitro response to vaccinia virus was associated with HLA-Cw3 both in 49 subjects tested three to four weeks after vaccination (P less than 0.001) and in the remaining 30 subjects tested five to 11 weeks after vaccination (P = 0.035). Responses to unrelated antigens and phytohemagglutinin of lymphocytes tested before, three to four weeks and five to 11 weeks after vaccination indicated that this association was specific for vaccinia virus and suggested that differences in immune response to vaccinia were reflected in temporarily altered immune responsiveness to unrelated antigens. Our results indicate that HLA-Cw3 or an HLA product associated with Cw3 is involved in the cellular immune response to vaccinia virus.

Adolescent↗